Arena Pharmaceuticals (NASDAQ:ARNA) Director Donald Belcher sold 4,176 shares of the company’s stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $7.00, for a total value of $29,232.00. Following the sale, the director now directly owns 68,728 shares of the company’s stock, valued at approximately $481,096. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) net profit margin is -24.00% and weekly performance is -6.72%. On last trading day company shares ended up $6.39. Analysts mean target price for the company is $8.06. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) distance from 50-day simple moving average (SMA50) is -1.69%.
InterMune (NASDAQ:ITMN) VP Sean Nolan sold 2,644 shares of InterMune stock in a transaction dated Thursday, May 8th. The stock was sold at an average price of $35.85, for a total value of $94,787.40. Following the completion of the sale, the vice president now directly owns 72,556 shares of the company’s stock, valued at approximately $2,601,133. InterMune Inc. (NASDAQ:ITMN) shares fell -0.08% in last trading session and ended the day on $35.41. ITMN gross Margin is 87.30% and its return on assets is -44.50%.InterMune Inc. (NASDAQ:ITMN) quarterly performance is 153.65%.
Questcor Pharmaceuticals (NASDAQ:QCOR) Insider Michael H. Mulroy sold 10,000 shares of the stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $87.99, for a total value of $879,900.00. Following the transaction, the insider now directly owns 77,063 shares in the company, valued at approximately $6,780,773. Questcor Pharmaceuticals Inc. (NASDAQ:QCOR) shares moved up 0.11% in last trading session and was closed at $87.16, while trading in range of $85.74 – $87.73. Questcor Pharmaceuticals Inc. (NASDAQ:QCOR) year to date (YTD) performance is 61.56%.
Sangamo Biosciences (NASDAQ:SGMO) Director John William Larson unloaded 10,000 shares of the stock on the open market in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $13.48, for a total transaction of $134,800.00. Following the sale, the director now directly owns 218,160 shares of the company’s stock, valued at approximately $2,940,797. Sangamo Biosciences, Inc. (NASDAQ:SGMO) ended the last trading day at $13.30. Company weekly volatility is calculated as 8.59% and price to cash ratio as 4.24.Sangamo Biosciences, Inc. (NASDAQ:SGMO) showed a positive weekly performance of 13.10%.
Illumina (NASDAQ:ILMN) Director Daniel Bradbury unloaded 2,100 shares of the company’s stock on the open market in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $146.46, for a total value of $307,566.00. Following the transaction, the director now directly owns 9,924 shares in the company, valued at approximately $1,453,469. Illumina, Inc. (NASDAQ:ILMN) shares moved down -2.79% in last trading session and was closed at $144.73, while trading in range of $144.00 – $150.50. Illumina, Inc. (NASDAQ:ILMN) year to date (YTD) performance is 30.87%.